To emphasize the critical importance of initiating cardiovascular (CV) disease prevention before conception and throughout pregnancy.
Key Findings:
Pre-conception health factors significantly influence pregnancy outcomes and future CV risk, necessitating early intervention.
Paternal health also affects offspring through epigenetic changes, which can have lasting implications for their cardiovascular health.
In utero disturbances can lead to lifelong cardiovascular programming, highlighting the need for monitoring during pregnancy.
Current clinical practices often overlook early risk assessment and intervention, which could prevent future cardiovascular issues.
Interpretation:
Effective CV disease prevention requires a paradigm shift to include pre-conception and pregnancy periods, recognizing that risk factors begin long before adulthood and must be addressed proactively.
Limitations:
Mainstream clinical care is slow to adopt a life-course approach to CV risk, often neglecting early intervention.
Existing risk assessment tools are primarily designed for middle-aged adults, limiting their applicability to younger populations.
Conclusion:
To achieve meaningful CV disease prevention, it is essential to integrate pre-conception and pregnancy health into the prevention narrative, leveraging early risk identification and intervention strategies to improve outcomes for mothers and children.
Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.
Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
